Your Voice, Our Headlines

Download Folkspaper App with no Ads!


A fast-growing newspaper curated by the online community.

Covid-19 updates : Pfizer chairman says, need to examine whether vaccinated people can still spread coronavirus.

  • tag_facesReaction
  • Tip Bones

The Chairman of Pfizer has said that it is yet to be examined whether those who are vaccinated from coronavirus can still spread the virus.

The vaccine was developed jointly by Pfizer and the smaller firm BioNTech.According to the report, researchers not associated with this vaccine's development, have highlighted how the company's trials did not assess whether the vaccine affects how the virus spreads.

According to a report in Business Insider, Albert Bourla told NBC's "Dateline" that more studies had to be done into whether a vaccinated person could still transmit the coronavirus.

Host Lester Holt asked Bourla: "Even though I've had the protection, am I still able to transmit it to other people?"Bourla then responded: "I think this is something that needs to be examined.

We are not certain about that right now with what we know."It raises the possibility that vaccinated people could still pass the disease to others, reported Business Insider.

Pfizer is still awaiting approval from the US as the US Food and Drug Administration (FDA ) is assembling independent experts on December 10 to evaluate the vaccine.

90-year-old UK woman is first in world to get Pfizer vaccine shot outside trial.

Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19

Pfizer Inc.

and BioNTech SE announced today that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2), against COVID-19.Pfizer Inc.

and BioNTech SE announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the U.S. by the middle to end of December 2020.Pfizer Inc.

and BioNTech SE today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints.

Informathub : Revue products